Announcing our next conference – the 4th NextGen Therapies in SJIA, Still’s & MAS Conference. We organize this conference about once in two years to have a focused conversation about advances in therapies for SJIA/Still’s & MAS, both whats approved and what’s coming down the pipeline.
The Jan 2022 conference will be fully virtual. The focus (as in previous NextGens) will be on refractory disease (when disease is not in control after 2 years / multiple medications). We will invite all stakeholders to the table – scientists, clinicians, patient and caregiver representatives, FDA / EMA and pharmaceutical companies.
- The conference will be virtual for the first time. We hope for participation from all across the world
- Will bring together all stakeholders – patients & caregiver representatives, researchers, clinicians, FDA/EMA and pharmaceutical companies
- Will Highlight patient perspective where possible
- Will focus on both pediatric & adult versions of disease – SJIA & Still’s
We will post soon again with more details but please save the dates!
If you have any comments / suggestions about the conference, do not hesitate to get in touch at email@example.com